{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:29:28Z","timestamp":1784305768464,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Front. Med."],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11684-025-1155-1","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T01:31:51Z","timestamp":1759282311000},"page":"820-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Albumin-bound paclitaxel plus anlotinib in patients with recurrent, platinum-resistant primary epithelial ovarian cancer (A-Plus): a phase II, single-arm, prospective study"],"prefix":"10.1007","volume":"19","author":[{"given":"Yun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongzhen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanjuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"3","key":"1155_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1155_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022; 135(5): 584\u2013590","journal-title":"Chin Med J (Engl)"},{"key":"1155_CR3","first-page":"100629","volume":"33","author":"S Sambasivan","year":"2022","unstructured":"Sambasivan S. Epithelial ovarian cancer: review article. Cancer Treat Res Commun 2022; 33: 100629","journal-title":"Cancer Treat Res Commun"},{"issue":"5","key":"1155_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/annonc\/mdz104","volume":"30","author":"M Buechel","year":"2019","unstructured":"Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol 2019; 30(5): 721\u2013732","journal-title":"Ann Oncol"},{"issue":"3","key":"1155_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","volume":"15","author":"FM Muggia","year":"1997","unstructured":"Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15(3): 987\u2013993","journal-title":"J Clin Oncol"},{"issue":"2","key":"1155_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","volume":"29","author":"J Sehouli","year":"2011","unstructured":"Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter Phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2011; 29(2): 242\u2013248","journal-title":"J Clin Oncol"},{"issue":"2","key":"1155_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","volume":"16","author":"PG Rose","year":"1998","unstructured":"Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16(2): 405\u2013410","journal-title":"J Clin Oncol"},{"issue":"3","key":"1155_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0090-8258(03)00399-8","volume":"90","author":"M Markman","year":"2003","unstructured":"Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 2003; 90(3): 593\u2013596","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1155_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","volume":"88","author":"PG Rose","year":"2003","unstructured":"Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 88(2): 130\u2013135","journal-title":"Gynecol Oncol"},{"key":"1155_CR10","doi-asserted-by":"publisher","first-page":"102224","DOI":"10.1016\/j.ctrv.2021.102224","volume":"98","author":"D An","year":"2021","unstructured":"An D, Banerjee S, Lee JM. Recent advancements of antiangiogenic combination therapies in ovarian cancer. Cancer Treat Rev 2021; 98: 102224","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1155_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/CCO.0b013e328363e0da","volume":"25","author":"D Shaw","year":"2013","unstructured":"Shaw D, Clamp A, Jayson GC. Angiogenesis as a target for the treatment of ovarian cancer. Curr Opin Oncol 2013; 25(5): 558\u2013565","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"1155_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ygyno.2015.08.011","volume":"139","author":"LR Duska","year":"2015","unstructured":"Duska LR, Java JJ, Cohn DE, Burger RA. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology\/gynecologiconcology group study (ADS-1236). Gynecol Oncol 2015; 139(2): 221\u2013227","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1155_CR13","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015; 16(8): 928\u2013936","journal-title":"Lancet Oncol"},{"issue":"13","key":"1155_CR14","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA openlabel randomized phase III trial. J Clin Oncol 2014; 32(13): 1302\u20131308","journal-title":"J Clin Oncol"},{"issue":"1","key":"1155_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3390\/jcm12010162","volume":"12","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Wang X, Chen Z, Zhou L, Di X, Fan P, He Z. Anlotinib suppressed ovarian cancer progression via inducing G2\/M phase arrest and apoptosis. J Clin Med 2022; 12(1): 162","journal-title":"J Clin Med"},{"key":"1155_CR16","doi-asserted-by":"publisher","first-page":"101767","DOI":"10.1016\/j.eclinm.2022.101767","volume":"54","author":"G Liu","year":"2022","unstructured":"Liu G, Feng Y, Li J, Deng T, Yin A, Yan L, Zheng M, Xiong Y, Li J, Huang Y, Zhang C, Huang H, Wan T, Huang Q, Lin A, Jiang J, Kong B, Liu J. A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: efficacy and safety results from the phase II, multi-center ANNIE study. EClinicalMedicine 2022; 54: 101767","journal-title":"EClinicalMedicine"},{"issue":"7","key":"1155_CR17","doi-asserted-by":"publisher","first-page":"100689","DOI":"10.1016\/j.xcrm.2022.100689","volume":"3","author":"CY Lan","year":"2022","unstructured":"Lan CY, Zhao J, Yang F, Xiong Y, Li R, Huang Y, Wang J, Liu C, Bi XH, Jin HH, Meng J, Zhao WH, Zhang L, Wang YF, Zheng M, Huang X. Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: a multi-center, single-arm, phase 1b trial. Cell Rep Med 2022; 3(7): 100689","journal-title":"Cell Rep Med"},{"issue":"11","key":"1155_CR18","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1136\/ijgc-2023-004777","volume":"33","author":"W Shen","year":"2023","unstructured":"Shen W, Jing C, Tian W, Zhang W, Ren Y, Shan B, Wang H. Anlotinib in patients with recurrent platinum resistant\/refractory ovarian cancer: a prospective, single arm, phase II study. Int J Gynecol Cancer 2023; 33(11): 1764\u20131770","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"1155_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ygyno.2012.08.039","volume":"128","author":"TD Tillmanns","year":"2013","unstructured":"Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ, Schwartzberg LS. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol 2013; 128(2): 221\u2013228","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1155_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ygyno.2011.04.005","volume":"122","author":"TJ Herzog","year":"2011","unstructured":"Herzog TJ, Vermorken JB, Pujade-Lauraine E, Provencher DM, Jagiello-Gruszfeld A, Kong B, Boman K, Park YC, Parekh T, Lebedinsky C, G\u00f3mez J, Monk BJ. Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study. Gynecol Oncol 2011; 122(2): 350\u2013355","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1155_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J; Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011; 21(2): 419\u2013423","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"1155_CR22","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","volume":"14","author":"GJ Rustin","year":"1996","unstructured":"Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H, Lambert HE. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14(5): 1545\u20131551","journal-title":"J Clin Oncol"},{"issue":"4","key":"1155_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","volume":"7","author":"GJ Rustin","year":"1996","unstructured":"Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996; 7(4): 361\u2013364","journal-title":"Ann Oncol"},{"issue":"Suppl1","key":"1155_CR24","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/S0923-7534(20)31480-0","volume":"10","author":"GJ Rustin","year":"1999","unstructured":"Rustin GJ, Nelstrop AE, Bentzen SM, Piccart MJ, Bertelsen K. Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol 1999; 10(Suppl 1): S21\u2013S27","journal-title":"Ann Oncol"},{"issue":"8","key":"1155_CR25","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1200\/JCO.2000.18.8.1733","volume":"18","author":"GJ Rustin","year":"2000","unstructured":"Rustin GJ, Nelstrop AE, Bentzen SM, Bond SJ, McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 2000; 18(8): 1733\u20131739","journal-title":"J Clin Oncol"},{"issue":"9","key":"1155_CR26","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1200\/JCO.2008.18.9548","volume":"27","author":"MG Teneriello","year":"2009","unstructured":"Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, Boehm KA, Williams A, Asmar L. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2009; 27(9): 1426\u20131431","journal-title":"J Clin Oncol"},{"issue":"1","key":"1155_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ygyno.2011.03.036","volume":"122","author":"RL Coleman","year":"2011","unstructured":"Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 122(1): 111\u2013115","journal-title":"Gynecol Oncol"},{"issue":"9","key":"1155_CR28","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1093\/annonc\/mds003","volume":"23","author":"KH Baumann","year":"2012","unstructured":"Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburg A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, Wagner U. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol 2012; 23(9): 2265\u20132271","journal-title":"Ann Oncol"},{"issue":"1","key":"1155_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ygyno.2021.08.005","volume":"163","author":"M Cowan","year":"2021","unstructured":"Cowan M, Swetzig WM, Adorno-Cruz V, Pineda MJ, Neubauer NL, Berry E, Lurain JR, Shahabi S, Taiym D, Nelson V, O\u2019Shea KL, Kocherginsky M, Matei D. Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial. Gynecol Oncol 2021; 163(1): 57\u201363","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1155_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ygyno.2015.04.009","volume":"138","author":"H Hirte","year":"2015","unstructured":"Hirte H, Lheureux S, Fleming GF, Sugimoto A, Morgan R, Biagi J, Wang L, McGill S, Ivy SP, Oza AM. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia. Gynecol Oncol 2015; 138(1): 55\u201361","journal-title":"Gynecol Oncol"},{"issue":"33","key":"1155_CR31","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","volume":"27","author":"UA Matulonis","year":"2009","unstructured":"Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27(33): 5601\u20135606","journal-title":"J Clin Oncol"},{"issue":"1","key":"1155_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2012.07.020","volume":"49","author":"UA Matulonis","year":"2013","unstructured":"Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer 2013; 49(1): 121\u2013131","journal-title":"Eur J Cancer"},{"issue":"15suppl","key":"1155_CR33","doi-asserted-by":"publisher","first-page":"e18078","DOI":"10.1200\/JCO.2020.38.15_suppl.e18078","volume":"38","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Chen J, Wei W, Zheng L, Li H, Feng Y, Wan T, Qiu J, Jiang X, Xiong Y, Li J, Song L, Liu J, Huang H. Anlotinib (AL3818) plus pemetrexed in patients with recurrent platinumresistant advanced epithelial ovarian cancer: a single-arm, openlabel, phase II study. J Clin Oncol 2020; 38(15 suppl): e18078","journal-title":"J Clin Oncol"},{"key":"1155_CR34","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.ygyno.2023.06.509","volume":"176","author":"X Zhang","year":"2023","unstructured":"Zhang X, Jiang M, Li T, Lan H, Ning C, Wang G. Anlotinib enhanced the efficacy of pembrolizumab in refractory or recurrent High-Grade Serous Ovarian Cancer by regulating the tumor microenvironment (LBA 7). Gynecol Oncol 2023; 176: S32","journal-title":"Gynecol Oncol"},{"key":"1155_CR35","doi-asserted-by":"publisher","first-page":"v422","DOI":"10.1093\/annonc\/mdz250.041","volume":"30","author":"D Miller","year":"2019","unstructured":"Miller D, Miller DS, Cheung E, Huang M, Schlumbrecht M, Garcia A, Loch M, Jernigan A, Li Z, Chen M, Chen J. Phase Ib\/IIa study assessing the safety and efficacy of adding AL3818 (anlotinib) to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian or cervical carcinoma. Ann Oncol 2019; 30: v422","journal-title":"Ann Oncol"},{"issue":"11","key":"1155_CR36","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol 2018; 4(11): 1569\u20131575","journal-title":"JAMA Oncol"},{"issue":"1","key":"1155_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","volume":"9","author":"Y Sun","year":"2016","unstructured":"Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C, Chi Y. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol 2016; 9(1): 105","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1155_CR38","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","volume":"33","author":"JS Frenel","year":"2022","unstructured":"Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, Pautier P, Ledermann JA, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Colombo N, Park-Simon TW, Tamura K, Sonke GS, Freimund AE, Lee CK, Pujade-Lauraine E. Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial. Ann Oncol 2022; 33(10): 1021\u20131028","journal-title":"Ann Oncol"},{"issue":"3","key":"1155_CR39","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ygyno.2018.11.028","volume":"152","author":"SA Foote Jr","year":"2019","unstructured":"Foote SA Jr, Liang MI, Ehrisman JA, Cohn DE, Jewell E, Havrilesky LJ. Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 2019; 152(3): 445\u2013451","journal-title":"Gynecol Oncol"},{"issue":"12","key":"1155_CR40","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","volume":"34","author":"E Pujade-Lauraine","year":"2023","unstructured":"Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marm\u00e9 F, Lindemann K, Colombo N, M\u0105dry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-P\u00e9rez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A; OReO\/ENGOT-ov38 investigators. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial. Ann Oncol 2023; 34(12): 1152\u20131164","journal-title":"Ann Oncol"},{"issue":"1","key":"1155_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1200\/JCO.2005.01.2757","volume":"24","author":"GJ Rustin","year":"2006","unstructured":"Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 2006; 24(1): 45\u201351","journal-title":"J Clin Oncol"}],"container-title":["Frontiers of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-025-1155-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11684-025-1155-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-025-1155-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T04:00:10Z","timestamp":1761796810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11684-025-1155-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1007\/s11684-025-1155-1","relation":{},"ISSN":["2095-0217","2095-0225"],"issn-type":[{"value":"2095-0217","type":"print"},{"value":"2095-0225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"17 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflicts of interest\n                      Yun Zhou, Jian Zhou, Ying Wang, Ji-Bin Li, Rongzhen Luo, Chanjuan Zeng, Yingxin He, and Yanfang Li declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This study was approved by the Ethical Committee of the Cancer Center, Sun Yat-sen University (Guangzhou, China) and was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR2100054329), and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all patients for being included in the study. The key raw data were deposited at the Sun Yat-sen University Cancer Center for future reference (RDDA2024521599).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}